Release Details

SAN DIEGO, May 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd., wet age-related macular degeneration, announced today that it will report its first quarter 2019 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2019. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.

A replay of the webcast will be available for 60 days on the website.

About TRACON

TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: DE-122, the ophthalmic formulation of carotuximab, an endoglin antibody, that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; TRC253, a small molecule being developed for the treatment of prostate cancer; and TJ004309, a CD73 antibody being developed for the treatment of advanced solid tumors. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.

Source: TRACON Pharmaceuticals, Inc.